The New High Cholesterol Guidelines Are Out — And Still Getting It Wrong

In March 2026, the American College of Cardiology and American Heart Association released new guidelines on the management of dyslipidemia. It was the first major update since 2018. I was hoping these guidelines finally caught up with the best evidence in lipidology but unfortunately they did not. The 2026 ACC/AHA Dyslipidemia Guideline is a step forward but not the leap we needed.

What They Got Right: Lp(a) Finally Gets Recommended

Let's start with the good news. For the first time, the guidelines recommend that all adults have their Lp(a) measured at least once in their lifetime. This is a significant and overdue win. Lp(a) is a genetically determined, highly atherogenic lipoprotein that affects roughly 1 in 5 people worldwide. But for decades it was treated as a footnote in cardiovascular risk assessment.

Lp(a) operates independently of LDL cholesterol. You can have a "normal" LDL and still be at dramatically elevated risk of heart attack and stroke because of elevated Lp(a). The new guideline acknowledges this, recommending that patients with high Lp(a) undergo more intensive cholesterol-lowering therapy. This is genuinely good medicine. Universal Lp(a) screening will identify millions of people who are flying blind on their cardiovascular risk.

What They Got Wrong: ApoB

ApoB is arguably the single most important lipid marker we have. Every atherogenic particle in your blood (every LDL, VLDL, IDL, and Lp(a) particle) carries exactly one ApoB molecule. That means ApoB is a direct count of the atherogenic particle burden in your bloodstream. It is more accurate than LDL-C. It is more predictive than non-HDL cholesterol. The evidence for this is overwhelming.

So what do the new guidelines do with ApoB? They recommend measuring it only after LDL-C and non-HDL-C goals have already been met. In other words, ApoB is treated as an afterthought rather than a primary tool.

This is a mistake, and a consequential one. LDL-C is a calculated estimate of cholesterol concentration in LDL particles. It is not a particle count. A person may have low LDL-C with an elevated particle number, badly underestimating true cardiovascular risk if only LDL-C is tested.

ApoB should be a universal first-line test ordered alongside LDL-C at every lipid panel, for every patient. The test is inexpensive, widely available, and provides information that LDL-C simply cannot. Instead, the guidelines relegate it to secondary status, ensuring that people will never have it ordered until there's already a problem. This leaves critical diagnostic information on the table, and people will pay for it with cardiovascular events that could have been prevented.

The LDL Treatment Threshold: Better, But Still Not Good Enough

The 2026 guideline recommends considering lipid-lowering therapy for young adults with LDL-C of 160 mg/dL or greater. This is an improvement over prior guidance.

But 160 mg/dL is still too high a bar, and here's why: cardiovascular disease is a process. Atherosclerosis begins accumulating in your arteries in your twenties and thirties, quietly and asymptomatically. Plaque doesn't care about your 10-year risk score. It cares about how long your arteries have been exposed to elevated atherogenic lipoproteins.

The concept of "cholesterol-years" or cumulative LDL exposure is increasingly well-supported in the literature. Just as we understand that decades of cigarette smoking causes far more damage than a few years, decades of moderately elevated LDL causes far more arterial damage than a brief period of high LDL. The guideline itself acknowledges this, quoting the principle that "lower for longer is better." Yet the treatment threshold doesn't reflect it.

A 35-year-old with an LDL of 140 mg/dL might look fine on a 10-year risk calculator. But if that LDL remains at 140 for the next 30 years, the cumulative exposure to atherogenic lipoproteins is enormous. We now have safe, effective, and increasingly affordable treatments that can meaningfully reduce that burden. Why are we waiting until LDL hits 160?

Critics of early treatment point to the risks of long-term medication and the modest absolute risk reduction in low-risk individuals. These are fair considerations. But they must be weighed against the equally real risk of untreated cumulative lipoprotein exposure over decades. The guidelines themselves noted that future updates should consider a lower LDL-C target across risk categories, a sign that even the authors recognize the current thresholds may be too conservative.

The Bigger Picture: Why Guidelines Lag Behind Science

Clinical guidelines are inherently conservative instruments. They are built on consensus, which means they tend to reflect the center of expert opinion rather than the frontier. They require high levels of evidence before making strong recommendations, which means emerging data often doesn't make the cut.

This conservatism serves an important purpose. Medicine has a long history of confident interventions that turned out to be wrong. Guideline committees are right to demand robust evidence before recommending population-wide treatment changes.

But conservatism has costs too. When guidelines lag behind the evidence, people don't get the benefit of what we know. Physicians anchor on guideline thresholds rather than using clinical judgment. Insurance companies cite guidelines to deny coverage for tests and treatments that fall outside their narrow recommendations.

The result is that the 2026 ACC/AHA guidelines, while better than 2018, still leave millions of people under-treated and under-tested.

What You Should Ask Your Physician

If you care about your long-term cardiovascular health here is what to ask your physician at your next visit:

• Has my Lp(a) level been checked? This is now recommended at least once for all adults. If it's elevated, your cardiovascular risk may be significantly higher than your LDL alone suggests.
• Can we check my ApoB? Even if your LDL looks normal, ApoB gives a more accurate picture of your atherogenic particle burden. It's especially important if you have diabetes, metabolic syndrome, or elevated triglycerides.
• What is my cumulative cholesterol exposure? If your LDL has been mildly or moderately elevated for years, that cumulative exposure matters. Ask your doctor about your 30 year cardiovascular risk, not just your 10-year risk.

The Bottom Line

The 2026 ACC/AHA Dyslipidemia Guideline is the best set of cholesterol guidelines the United States has ever had. It restores LDL-C treatment targets, embraces lifetime risk thinking, and finally brings Lp(a) into routine clinical care. These are meaningful advances.

But the guidelines are still not good enough. By relegating ApoB to secondary status and setting the primary treatment threshold at LDL ≥ 160 mg/dL, the guidelines leave significant preventive opportunity unrealized. Cardiovascular disease will continue to kill people who, by current guideline standards, didn't quite meet the threshold for earlier intervention.

All materials contained in this blog post are for informational purposes only and should not be construed as medical advice. Please consult with your physician concerning any and all medical questions and/or problems.